During the past decade, Dekalb Gastroenterology Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Dekalb Gastroenterology Associates" are "Hepatitis C, Chronic" (3 trials), "Inflammatory Bowel Disease" (1 trials) and "Ulcerative Colitis" (1 trials). Many other conditions were trialed in "Dekalb Gastroenterology Associates" in a lesser frequency.

Most popular intervention types in "Dekalb Gastroenterology Associates" are "Drug" (3 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Balsalazide Disodium" (1 trials), "Copegus®" (1 trials), "GS-5885 tablet" (1 trials), "GS-9451" (1 trials) and "GS-9451 placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dekalb Gastroenterology Associates" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Dekalb Gastroenterology Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Dekalb Gastroenterology Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dekalb Gastroenterology Associates, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".